Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Decline in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 640,200 shares, a decline of 23.4% from the April 30th total of 835,700 shares. Based on an average daily volume of 170,500 shares, the days-to-cover ratio is currently 3.8 days. Currently, 15.2% of the company’s stock are short sold.

Aligos Therapeutics Stock Down 6.1%

NASDAQ:ALGS opened at $5.39 on Monday. The firm has a market capitalization of $32.95 million, a price-to-earnings ratio of -0.40 and a beta of 2.76. Aligos Therapeutics has a twelve month low of $3.76 and a twelve month high of $46.80. The stock’s 50 day moving average price is $5.66 and its two-hundred day moving average price is $18.76.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Tuesday, May 6th. The company reported ($2.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.80) by $0.69. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.33 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. As a group, analysts anticipate that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its holdings in shares of Aligos Therapeutics by 2,073.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock worth $26,000 after acquiring an additional 622 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Aligos Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company’s stock worth $44,000 after acquiring an additional 2,674 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Aligos Therapeutics during the 1st quarter worth approximately $130,000. Northern Trust Corp acquired a new position in shares of Aligos Therapeutics during the 4th quarter worth approximately $205,000. Finally, Readystate Asset Management LP acquired a new position in shares of Aligos Therapeutics during the 1st quarter worth approximately $375,000. 60.43% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Aligos Therapeutics in a research report on Monday, March 31st.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).